Abstract 1271P
Background
Understanding the associates and causes of progression after first-line treatment in EGFR-mutant advanced NSCLC remains a critical yet elusive endeavor. In this study, we employed a comprehensive approach integrating machine learning classification and causal inference analysis to unveil the determinants of progression in this patient cohort.
Methods
Retrospective data from eleven academic centers were gathered to compile a cohort of EGFR mutant patients. Classical patient features, treatment characteristics, and the neutrophil to lymphocyte ratio (NLR) at the onset of first-line treatment were analyzed. Fifteen machine learning algorithms were employed to identify the optimal model, evaluated based on F1 score and area under the curve (AUC). Additionally, Linear Non-Gaussian Acyclic Model (LINGAM) was utilized for causal inference analysis to delineate the causal relationships driving progression.
Results
Among 333 patients initially evaluated, 205 cases were deemed suitable for machine learning analysis after accounting for missing data and follow-up duration. Linear discriminant analysis emerged as the most accurate model, achieving an AUC of 0.74 and an F1 score of 0.77. The top three influential variables identified by this model were smoking status, NLR category, and type of first-line treatment with variable importance scores of 1.2, 0.8, and 0.6, respectively. Moreover, LINGAM analysis revealed NLR category, smoking status, and gender as causal factors for progression, with causal estimate scores of -0.20, -0.17, and -0.04, respectively.
Conclusions
This study represents a pioneering effort in utilizing machine learning to explore the determinants of progression after first-line treatment in EGFR-mutant, advanced NSCLC. Our findings underscore the roles of smoking status, NLR category, and type of first-line treatment in driving progression. Furthermore, the causal inference analysis sheds light on smoking status, NLR category, and gender as causally significant factors. This understanding paves the way for elucidating the pathogenesis and developing novel therapeutic strategies for EGFR-mutant advanced NSCLC.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work the authors used ChatGpt 3.5 in order to enhance readibility. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1292P - A national real-world analysis of ROS1+ metastatic non-small cell lung cancer patients management (explore ALK, cohort 2, GFPC 03-2019)
Presenter: Gaelle Rousseau Bussac
Session: Poster session 05
1293P - Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial
Presenter: Ben Solomon
Session: Poster session 05
1294P - Non-adenocarcinoma histology in patients with RET+ lung cancer: Response to RET-inhibitors and survival from the RET-MAP registry
Presenter: Arianna Marinello
Session: Poster session 05
1295P - EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI
Presenter: Elena Garralda
Session: Poster session 05
1296P - A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification
Presenter: Caicun Zhou
Session: Poster session 05
1297P - A phase II study of pyrotinib combined with apatinib in first-line treatment of advanced non-small cell lung cancer patients with primary HER-2 mutations/amplification
Presenter: Wenxin Jiang
Session: Poster session 05
1299P - First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
Presenter: Alessandro Di Federico
Session: Poster session 05
1300P - Treatment sequences in BRAF-V600-mutant non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
Presenter: Marcel Wiesweg
Session: Poster session 05
1301P - BRAF-mutant metastatic non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database
Presenter: Alessandro Russo
Session: Poster session 05